Show simple item record

dc.rights.licenseAttribution 4.0 International (CC BY 4.0)
dc.creatorZhang, Hongxia
dc.creatorSun, Fen
dc.creatorWang, Jixian
dc.creatorXie, Luokun
dc.creatorYang, Chenqi
dc.creatorPan, Mengxiong
dc.creatorShao, Bei
dc.creatorYang, Guo-Yuan
dc.creatorYang, Shao-Hua
dc.creatorZhuge, Qichuan
dc.creatorJin, Kunlin
dc.date.accessioned2022-09-09T14:08:39Z
dc.date.available2022-09-09T14:08:39Z
dc.date.issued2017-04-01
dc.identifier.citationZhang, H., Sun, F., Wang, J., Xie, L., Yang, C., Pan, M., Shao, B., Yang, G. Y., Yang, S. H., ZhuGe, Q., & Jin, K. (2017). Combining Injectable Plasma Scaffold with Mesenchymal Stem/Stromal Cells for Repairing Infarct Cavity after Ischemic Stroke. Aging and disease, 8(2), 203-214. https://doi.org/10.14336/AD.2017.0305
dc.identifier.issn2152-5250
dc.identifier.urihttps://hdl.handle.net/20.500.12503/31688
dc.description.abstractStroke survivors are typically left with structural brain damage and associated functional impairment in the chronic phase of injury, for which few therapeutic options exist. We reported previously that transplantation of human embryonic stem cell (hESC)-derived neural stem cells together with Matrigel scaffolding into the brains of rats after focal ischemia reduced infarct volume and improved neurobehavioral performance. Matrigel is a gelatinous protein mixture extracted from mouse sarcoma cells, thus would not be approved for use as a scaffold clinically. In this study, we generated a gel-like scaffold from plasma that was controlled by changing the concentration of CaCl2. In vitro study confirmed that 10-20 mM CaCl2 and 10-40% plasma did not affect the viability and proliferation of human and rat bone marrow mesenchymal stem/stromal cells (BMSCs) and neural stem cells (NSCs). We transplanted plasma scaffold in combination of BMSCs into the cystic cavity after focal cerebral ischemia, and found that the atrophy volume was dramatically reduced and motor function was significantly improved in the group transplanted with scaffold/BMSCs compared with the groups treated with vehicle, scaffold or BMSCs only. Our data suggest that plasma-derived scaffold in combination of BMSCs is feasible for tissue engineering approach for the stroke treatment.
dc.description.sponsorshipThis work was supported by National Institute of Health (NIH) grants NS094859, AG21980 and NS057186 to K Jin and by grants from National Science Foundation of China (81371396) and from the Ministry-Province Jointly Constructed Base (WKJ2013-2-022) to Q Zhuge.
dc.publisherJKL International
dc.relation.urihttps://doi.org/10.14336/AD.2017.0305
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceAging and Disease
dc.subjectaging
dc.subjectaging-related diseases
dc.subjectdiagnosis
dc.subjectfrailty
dc.subjectregulation
dc.subjectsenescence
dc.titleCombining Injectable Plasma Scaffold with Mesenchymal Stem/Stromal Cells for Repairing Infarct Cavity after Ischemic Stroke
dc.typeArticle
dc.rights.holder© 2017.
dc.type.materialtext
dc.creator.orcid0000-0002-1336-348X (Jin, Kunlin)
dc.creator.orcid0000-0002-0405-0887 (Yang, Shaohua)
dc.creator.orcid0000-0003-1594-6707 (Zhang, Hongxia)
dc.identifier.volume8
dc.identifier.issue2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)